You are here

  • Home
  • Archive
  • Volume 82, Issue 4
  • Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’

Article Text

Article menu

This article has a Reply. Please see:

Download PDFPDF
Correspondence
Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’
  1. Young Ho Lee
  1. Rheumatology, Korea University, Seoul, Seongbuk-gu, Korea (the Republic of)
  1. Correspondence to Professor Young Ho Lee, Rheumatology, Korea University, Seoul 02841, Korea (the Republic of); lyhcgh{at}korea.ac.kr

http://dx.doi.org/10.1136/annrheumdis-2021-219904

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The paper by Akiyama et al 1 on the prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases was an interesting read. This systematic review and meta-analysis indicates that glucocorticoid usage increases the risk of developing COVID-19, while monotherapy with biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs, particularly antitumour necrosis factor (TNF) monotherapy, has been associated with a decreased risk of developing severe COVID-19 and related mortality.1 However, certain methodological issues in this meta-analysis study need to be addressed. First, the efficacy and safety of glucocorticoid usage in patients …

    View Full Text

    Footnotes

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles